Temozolomide as a Single Agent or in Combination for Patients with High Risk Refractory or Relapsed Neuroblastoma: Excellent Tolerance and Sustained Disease Responses

被引：0
|
作者：
Metayer, L. [1 ]
Annereau, M. [2 ]
Abbas, R. [3 ]
Hinterlang, M. [2 ]
Schleiermacher, G. [4 ]
Defachelles, A. S. [5 ]
Pasqualini, C. [1 ]
Berlanga, P. [1 ]
Vassal, G. [6 ]
Valteau-Couanet, D. [1 ]
机构：
[1] Gustave Roussy, Dept Childhood & Adolescent Oncol, Villejuif, France
[2] Gustave Roussy, Dept Pharm, Villejuif, France
[3] Gustave Roussy, Dept Biostat & Epidemiol, Villejuif, France
[4] Inst Curie, Dept Paediat Oncol, Paris, France
[5] Ctr Oscar Lambret, Dept Paediat Oncol, Lille, France
[6] Gustave Roussy, Dept Clin Res, Villejuif, France
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FP052 SIOP
引用
收藏
页码：S33 / S34
页数：2
相关论文
共 50 条
  • [1] Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
    DuBois, Steven G.
    Mosse, Yael P.
    Fox, Elizabeth
    Kudgus, Rachel A.
    Reid, Joel M.
    McGovern, Renee
    Groshen, Susan
    Bagatell, Rochelle
    Maris, John M.
    Twist, Clare J.
    Goldsmith, Kelly
    Granger, M. Meaghan
    Weiss, Brian
    Park, Julie R.
    Macy, Margaret E.
    Cohn, Susan L.
    Yanik, Greg
    Wagner, Lars M.
    Hawkins, Randall
    Courtier, Jesse
    Lai, Hollie
    Goodarzian, Fariba
    Shimada, Hiroyuki
    Boucher, Najee
    Czarnecki, Scarlett
    Luo, Chunqiao
    Tsao-Wei, Denice
    Matthay, Katherine K.
    Marachelian, Araz
    CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6142 - 6149
  • [2] A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma
    Mitchell, Deanna
    Bergendahl, Genevieve
    Ferguson, William
    Roberts, William
    Higgins, Timothy
    Ashikaga, Takamaru
    DeSarno, Mike
    Kaplan, Joel
    Kraveka, Jacqueline
    Eslin, Don
    Werff, Alyssa Vander
    Hanna, Gina K.
    Sholler, Giselle L. Saulnier
    PEDIATRIC BLOOD & CANCER, 2016, 63 (01) : 39 - 46
  • [3] Disease control in patients treated with naxitamab for refractory/relapsed high-risk neuroblastoma
    Mora, Jaume
    Chan, Godfrey C.
    Morgenstern, Daniel A.
    Amoroso, Loredana
    Nysom, Karsten
    Faber, Joerg
    Wingerter, Arthur
    Bear, Melissa
    Rubio-San-Simon, Alba
    Tornoe, Karen
    Koep, Sharif
    During, Maria
    Kushner, Brian H.
    CANCER RESEARCH, 2024, 84 (17)
  • [4] Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma
    Mody, Rajen
    Zhao, Lili
    Yanik, Gregory Anthony
    Opipari, Valerie
    PEDIATRIC BLOOD & CANCER, 2017, 64 (11)
  • [5] A phase I trial of TPI-287 as a single agent and its combination with temozolomide in relapsed neuroblastoma or medulloblastoma
    Sholler, G. L. Saulnier
    Bergendahl, G.
    Lenox, S.
    Zage, P. E.
    Roberts, W.
    Kraveka, J. M.
    Eslin, D.
    Kaplan, J.
    Higgins, T.
    Ferguson, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma
    Larrosa, Crstina
    Simao Rafael, Margarida
    Pablo Munoz, Juan
    Gorostegui, Maite
    Castaneda Heredia, Alicia
    Garraus, Moira
    Mora, Jaume
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Phase I trial of TPI 287 as a single agent and in combination with temozolomide (TMZ) in patients with refractory or recurrent neuroblastoma (NB) or medulloblastoma (MB).
    Sholler, G. L. Saulnier
    Eslin, D.
    Roberts, W. D.
    Kaplan, J.
    Bergendahl, G.
    Ashikaga, T.
    Higgins, T.
    Lenox, S.
    Silberman, S.
    Ferguson, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] A phase I study of Aurora kinase A inhibitor LY3295668 erbumine as a single agent and in combination in patients with relapsed/refractory neuroblastoma.
    DuBois, Steven G.
    Kremer, Jill D.
    De Wilde, Bram
    Jacobsen, Chad
    Aerts, Isabelle
    Mosse, Yael P.
    Maris, John M.
    Lithio, Andrew
    Gosberg, Andreas
    Banks, C. L.
    Tate, Courtney
    Dowless, Michele
    Gong, Xueqian
    Stancato, Louis
    Bell-McGuinn, Katherine M.
    Park, Julie R.
    Pearson, Andrew Dj
    Marachelian, Araz
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Prognosis of Patients with Relapsed, High-risk Neuroblastoma: A Single Center Experience
    Yamada, Yuji
    Kiyotani, Chikako
    Shioda, Yoko
    Osumi, Tomoo
    Kato, Motohiro
    Tomizawa, Daisuke
    Terashima, Keita
    Hishiki, Tomoro
    Fujino, Akihiro
    Kanamori, Yutaka
    Fuji, Hiroshi
    Yoshioka, Takako
    Miyazaki, Osamu
    Matsumoto, Kimikazu
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S41 - S42
  • [10] Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial
    DuBois, Steven G.
    Marachelian, Araz
    Fox, Elizabeth
    Kudgus, Rachel A.
    Reid, Joel M.
    Groshen, Susan
    Malvar, Jemily
    Bagatell, Rochelle
    Wagner, Lars
    Maris, John M.
    Hawkins, Randall
    Courtier, Jesse
    Lai, Hollie
    Goodarzian, Fariba
    Shimada, Hiroyuki
    Czarnecki, Scarlett
    Tsao-Wei, Denice
    Matthay, Katherine K.
    Mosse, Yael P.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (12) : 1368 - +
12345